TD Waterhouse Canada Inc. Increases Holdings in Novartis AG $NVS

TD Waterhouse Canada Inc. lifted its holdings in Novartis AG (NYSE:NVS) by 15.8% in the second quarter, Holdings Channel reports. The fund owned 86,457 shares of the company’s stock after purchasing an additional 11,791 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Novartis were worth $13,322,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in NVS. SOA Wealth Advisors LLC. boosted its stake in shares of Novartis by 4,316.2% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 14,750 shares of the company’s stock worth $2,312,000 after purchasing an additional 14,416 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Novartis by 40.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock worth $30,715,000 after purchasing an additional 56,424 shares during the period. Mission Wealth Management LP lifted its stake in Novartis by 85.7% in the second quarter. Mission Wealth Management LP now owns 19,690 shares of the company’s stock worth $3,086,000 after purchasing an additional 9,086 shares during the last quarter. Brighton Jones LLC boosted its position in shares of Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after buying an additional 2,666 shares during the period. Finally, Presilium Private Wealth LLC purchased a new position in shares of Novartis during the first quarter valued at approximately $703,000. 13.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Stock Down 1.9%

NYSE:NVS opened at $159.95 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The company has a 50-day moving average of $155.74 and a 200 day moving average of $153.78. The firm has a market cap of $305.21 billion, a PE ratio of 24.13, a price-to-earnings-growth ratio of 3.12 and a beta of 0.45.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. As a group, research analysts anticipate that Novartis AG will post 8.84 EPS for the current fiscal year.

Novartis News Roundup

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported that remibrutinib met the primary endpoint in two Phase 3 trials for relapsing multiple sclerosis. The result supports the potential expansion of the drug beyond its existing development opportunities. Novartis Remibrutinib Phase 3 Trial Results
• Neutral Sentiment: Novartis’ recent Basel-related move and a reported multibillion-dollar investment to improve how an existing medicine is delivered point to a shift in strategic priorities. The initiative could support product differentiation and lifecycle management, although its financial impact is not yet clear. Novartis Basel Strategic Move
• Neutral Sentiment: Options traders purchased a large volume of Novartis put contracts, signaling increased near-term hedging or bearish speculation. This reflects market sentiment rather than a change in the company’s fundamentals. Novartis Put Option Activity
• Negative Sentiment: Novartis and partner Ionis Pharmaceuticals said pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial. The setback weakens the outlook for a closely watched treatment targeting lipoprotein(a), a major potential growth opportunity in cardiovascular medicine. Pelacarsen Late-Stage Trial Failure
• Negative Sentiment: Novartis paused eight experimental rap-cel CAR-T trials after three patient deaths linked to severe immune reactions. The safety issue threatens development of the company’s autoimmune and neurological cell-therapy programs and raises regulatory and disclosure concerns. Novartis CAR-T Trial Halt
• Negative Sentiment: Erste Group Bank lowered its earnings estimates for Novartis, adding pressure to expectations for future results. Combined with the pelacarsen failure and CAR-T safety pause, the revisions reinforce concerns about pipeline execution. Erste Group Cuts Novartis Earnings Estimates

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.